On February 6th, regulatory filings revealed that Novartis AG has submitted an application in China for the approval of ianalumab. Ianalumab is a fully human monoclonal antibody targeting the BAFF-R receptor, which Novartis obtained through its acquisition of MorphoSys. The drug features a dual mechanism of action, depleting B cells while also inhibiting the BAFF-R pathway. It is intended for the treatment of various autoimmune conditions, including Sjögren's syndrome, immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). This medication is the first anti-BAFF-R antibody to have completed Phase III clinical studies.